Navigation Links
BioMotiv Secures $46 Million in Funding

CLEVELAND, Aug. 5, 2013 /PRNewswire-USNewswire/ -- BioMotiv, a drug development accelerator based in Cleveland, Ohio, today announced that it has increased its total capital from investors to $46 million, adding Nationwide Mutual Insurance Company and several individual investors to its founding investors, University Hospitals of Cleveland and the Harrington Family.  Nationwide Mutual Insurance Company also will appoint a representative to serve on the Board of Managers of BioMotiv. 


"BioMotiv is a new business model for accelerating breakthrough discoveries into medicines, aligning capital and collaborations to develop a portfolio of therapeutics," said Baiju R. Shah, Chief Executive Officer of BioMotiv.  "This support from local institutions and investors provides the company a strong foundation on which to build nationally."

Launched last year, BioMotiv has established its organization and operations and attracted a world-renowned advisory board that includes several former heads of global pharmaceutical research and development organizations to manage a portfolio of promising drug technologies.  The company is affiliated with The Harrington Project for Discovery and Development, a $250 million national initiative initiated by University Hospitals.

"We license early-stage technologies and then develop them with the oversight of our experienced team and network of partners," said Shah.  BioMotiv has begun work on several promising technologies sourced from research institutions and industry sources.

BioMotiv continues to seek additional early-stage therapeutic technologies that are at the pre-clinical or early-clinical stage of development. 

About The Harrington Project

The Harrington Project for Discovery and Development is a $250 million national initiative to support the discovery and development of breakthrough discoveries by physician-scientists.  The Harrington Project, centered at University Hospitals Case Medical Center, is a new and powerful national model that addresses a set of challenges in advancing medicine through its innovative approach.  It includes the Harrington Discovery Institute and BioMotiv. The project, powered by a generous gift and investment from the Harrington family, successful entrepreneurs and recognized philanthropists in Cleveland, provides a comprehensive model to advance discoveries into development and to create novel therapies for patient care.

For more information about the Harrington Discovery Institute, go to:

For more information about BioMotiv, go to:

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMotiv Secures $21 million in Initial Funding
2. BioMotiv Names New Chief Executive Officer
3. Stark Medical Secures GSA Schedule Contract, Looks to Supply VA
4. NGM Biopharmaceuticals Secures $50 Million in Series C Financing to Advance its Portfolio of Novel Therapies for Diabetes and Obesity
5. Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies
6. SecureState Identifies Top 5 Vulnerabilities Facing Hospitals and Medical Device Manufactures
7. Aviir Secures Third $10 Million Financing Tranche To Fund Expanded Sales Of New Heart Risk Test
8. Chronic Kidney Disease: Reducing Risks of Progression-- Prismic Pharmaceuticals Secures Exclusive Licensing Rights
9. United Spinal Secures Victory in Protecting Access to Complex Rehab Technology in Washington State
10. Alimera Sciences Secures $20 Million Debt Facility
11. Henry Schein Secures $300 Million Of Committed Financing
Post Your Comments:
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "Radioimmunoassay Market ... User (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic ... - Global Forecast to 2020" report ... ) has announced the addition of the ...
(Date:11/25/2015)...  Amgen (NASDAQ: AMGN ) today announced the ... the United States (U.S.) Food and ... to Humira ® (adalimumab). Amgen believes this submission ... FDA and represents Amgen,s first BLA submission using the ... M.D., executive vice president of Research and Development at ...
(Date:11/25/2015)... -- On Tuesday, November 24, 2015, the jury ... Medical Technology, Inc. for product liability and misrepresentation ... device, awarded $11 million in favor of Plaintiff ... three days of deliberations, the jury found that ... and unreasonably dangerous, and that Wright Medical made ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ... 27th edition of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, ... The digital component is distributed nationally, through a vast social media strategy and ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television ... an interesting show that delves into an array of issues that are presently affecting ... benefit from open dialogue, this show is changing the subjects consumers focus on, one ...
(Date:11/27/2015)... Santa Rosa, CA (PRWEB) , ... November 27, 2015 , ... ... Northern California Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine ... dinner meeting. They observed that both STEMI and Sepsis conditions present in similar ways ...
(Date:11/26/2015)... Toronto, ON and Cambridge, ON (PRWEB) , ... ... ... announced today the availability of a real-time eReferral system for diagnostic imaging in ... CTs, ultrasounds, X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic ...
(Date:11/26/2015)... Mass. (PRWEB) , ... November 26, 2015 , ... ... thorough second medical opinion process, participated in the 61st annual Employee Benefits Conference. ... Plans and took place Sunday, November 8th through Wednesday, November 11th, 2015. The ...
Breaking Medicine News(10 mins):